
First subject enrolled in MUSC Hollings’ Phase II/III trial of HNSCC treatment
The Medical University of South Carolina (MUSC) Hollings Cancer Center, US, has enrolled the first subject in the Phase II/III FORTIFI-NH01 trial of ficerafusp alfa to treat individuals with human papillomavirus (HPV)-negative head and neck squamous …